Flipped Out: Structure-Guided Design of Selective Pyrazolylpyrrole ERK Inhibitors.
Aronov, A.M., Baker, C., Bemis, G.W., Cao, J., Chen, G., Ford, P.J., Germann, U.A., Green, J., Hale, M.R., Jacobs, M., Janetka, J.W., Maltais, F., Martinez-Botella, G., Namchuk, M.N., Straub, J., Tang, Q., Xie, X.(2007) J Med Chem 50: 1280-1287
- PubMed: 17300186 
- DOI: https://doi.org/10.1021/jm061381f
- Primary Citation of Related Structures:  
2OJG, 2OJI, 2OJJ, 2OK1 - PubMed Abstract: 
The Ras/Raf/MEK/ERK signal transduction is a key oncogenic pathway implicated in a variety of human cancers. We have identified a novel series of pyrazolylpyrroles as inhibitors of ERK. Aided by the discovery of two distinct binding modes for the pyrazolylpyrrole scaffold, structure-guided optimization culminated in the discovery of 6p, a potent and selective inhibitor of ERK.
Organizational Affiliation: 
Vertex Pharmaceuticals Inc., 130 Waverly Street, Cambridge, Massachusetts 02139-4242, USA. alex_aronov@vrtx.com